German pharmaceutical company Medac is cooperating with Scienta Lab to generate insights in rheumatology care using artificial intelligence (AI).

Scienta Lab, an AI company based in France, leverages multimodal data to support a better understanding of immuno-inflammatory diseases and their variability at the patient level. With this collaboration, Medac aims at gaining a better understanding of patients’ daily therapy routine.

The use of AI is being intensively discussed in rheumatology. Medac has already underlined its commitment to ideas and digital options by initiating the Ekipa Innovate Rheumatology challenge. As part of this challenge, the company deepened the contact with Scienta Lab. Both companies have now concluded a cooperation agreement.

The aim is to gain more information about patients’ everyday therapy lives.

Scienta Lab will apply its proprietary technology on real world data to extract medical concepts and identify patterns. This research will give Medac the opportunity to gain more insights into the everyday therapy of patients with rheumatological diseases.

“We are very pleased about the opportunity to find out more about the therapy situation of our patients with rheumatological diseases,” said Heiner Will, managing director of Medac. “With the new insights, we hope to better understand the patients’ situation so that we can better respond to their needs.”

Camille Bouget, CEO of Scienta Lab, added: “We are pleased to collaborate with Medac, an independent group developing medicinal treatments. This partnership demonstrates the commitment of Medac to support a personalised therapy journey in rheumatology thanks to innovations. Since its creation, Scienta Lab has been focused on pioneering the AI-powered precision immunology revolution, and we are pleased to join forces with Medac in the pursuit of this goal.”

Scienta Lab (www.scientalab.com) is a deeptech company harnessing AI to pioneer precision immunology. With its proprietary technology based on a foundation model, it leverages multimodal data to support a better understanding of immuno-inflammatory diseases physiopathology and variability at the patient level

Medac (www.medac.de) is a privately-owned German pharmaceutical company with sites in Wedel and Tornesch. It medicinal products are used worldwide to help doctors and patients manage acute and chronic diseases in the fields of oncology and haematology, urology, and autoimmune diseases. It also develops and distributes specialist diagnostic systems. Since 1970, Medac has been committed to its approach of uniting therapeutic and diagnostic products under one roof.